DNB Theory Anesthesia - Answers

Q1. How does the N-Methyl D-Aspartate (NMDA) Receptor Work in Pain? (10 Marks)

Introduction

Anatomy of the NMDA Receptor

• Ligand-gated ion channel permeable to Na⁺, K⁺, and crucially Ca²⁺
• Blocked tonically by Mg²⁺ at resting membrane potential (voltage-dependent block)
• Requires co-agonism: simultaneous binding of glutamate (at NMDA site) and glycine (at glycine site) for activation
• Located on dorsal horn neurons of the spinal cord (postsynaptic) and in supraspinal structures

Normal Pain Transmission (Low-Frequency Input)

1. Peripheral nociceptors (A-delta and C fibers) release glutamate and Substance P at the spinal dorsal horn
2. At low/short-lasting stimulation, glutamate only activates AMPA receptors producing short-lasting, limited depolarization
3. NMDA receptors remain blocked by Mg²⁺ - minimal calcium influx occurs
4. Signal is modulated by inhibitory interneurons using GABA and glycine

NMDA Receptor Activation in Persistent/High-Frequency Pain

1. Persistent depolarization from repeated AMPA receptor activation displaces the Mg²⁺ block from NMDA channels
2. Glutamate now binds the NMDA receptor → massive Ca²⁺ influx
3. Substance P co-released by C fibers activates NK1 tachykinin receptors → further increases NMDA conductance
4. This leads to the phenomenon of "wind-up" - a progressive amplification (temporal summation) of dorsal horn neuron excitability

Wind-Up and Central Sensitization

• Wind-up: Short-lived amplification of dorsal horn response to repetitive C-fiber stimulation; NMDA-dependent; potentially reversible
• Central sensitization: Longer-lasting change due to phosphorylation of NMDA receptors and other ion channels/regulatory proteins (serine/threonine kinase, tyrosine kinase pathways); leads to allodynia and hyperalgesia
• Ca²⁺ influx through NMDA channels activates intracellular kinases (PKC, PKA, CaMKII), prostanoids, and nitric oxide synthase (NO)
• NO acts as a retrograde messenger further amplifying presynaptic glutamate release

Consequences of Persistent NMDA Activation

• Peripheral sensitization: Reduced threshold of peripheral nociceptors (autosensitization)
• Central sensitization: Prolonged, enhanced pain even with minor stimuli
• Modification: Gene-level changes, A-fiber sprouting into C-fiber laminae → tactile allodynia, refractory chronic pain
• Clinical relevance: fibromyalgia, complex regional pain syndrome, osteoarthritis pain, post-surgical chronic pain

NMDA Receptor and Opioid Tolerance

• NMDA receptor activation contributes to opioid tolerance and hyperalgesia
• NMDA antagonists (ketamine) can block or reverse opioid tolerance by reducing descending medullary pain facilitation
• This is the basis for sub-anesthetic ketamine infusions as opioid-sparing therapy in the perioperative period

Drugs Acting on NMDA Receptors in Pain

Summary

Q2. Anticoagulation in ICU (10 Marks)

Introduction

1. Therapeutic - treatment of established thrombosis (DVT, PE, HIT, ECMO, CRRT circuit)
2. Prophylactic - prevention of VTE in critically ill immobilized patients

A. VTE Prophylaxis in the ICU

• Low molecular weight heparin (LMWH): enoxaparin 40 mg SC once daily is first choice per ASH guidelines; preferred over UFH in most ICU patients
• Unfractionated heparin (UFH): 5000 units SC every 8-12 hours; used when LMWH is contraindicated (severe renal impairment - CrCl <30 mL/min)
• Fondaparinux: used in HIT; 2.5 mg SC daily

B. Anticoagulation for Renal Replacement Therapy (CRRT/CKRT) in ICU

• Citrate chelates Ca²⁺ in the extracorporeal circuit - anticoagulates the circuit only (regional)
• Calcium infused separately into the venous return to restore systemic calcium
• Benefits: lowest hemorrhage rates, greatest filter life extension
• Protocol: 4% trisodium citrate into the arterial line; postfilter ionized Ca²⁺ target < 0.35 mmol/L
• Monitor: systemic ionized Ca²⁺, citrate accumulation (suspect if total Ca/ionized Ca ratio >2.5)
• Risks: metabolic alkalosis, hypernatremia, citrate toxicity in liver failure

• Initial bolus: 25-30 U/kg, followed by infusion 5-20 U/kg/hr
• Target: venous line APTT 1.5-2 times control
• Advantages: cheap, reversible with protamine, easy monitoring (APTT, ACT)
• Risks: bleeding (25-30%), HIT (3-5%), hyperkalemia, elevated transaminases

• Less predictable in CRRT; requires anti-Xa monitoring
• Preferred in some countries; not suitable in renal failure without dose adjustment

C. Anticoagulation in Specific ICU Scenarios

• Use the 4Ts score to assess probability
• If intermediate/high risk: immediately stop all heparin
• Use alternative anticoagulant: argatroban (direct thrombin inhibitor, hepatically cleared - preferred in renal failure), bivalirudin, or danaparoid
• DO NOT use warfarin in acute HIT (risk of limb gangrene due to protein C depletion)

• Systemic heparin anticoagulation mandatory
• Target ACT 180-220 seconds or anti-Xa 0.3-0.7 U/mL
• Heparin-bonded circuits can reduce systemic anticoagulation requirements

• Therapeutic-dose heparin anticoagulation improved survival and reduced need for organ support in non-ICU patients (ATTACC/ACTIV-4a/REMAP-CAP trial)
• In ICU patients with COVID-19, therapeutic anticoagulation did NOT show superiority over prophylactic dosing

• Rate control first; anticoagulation depends on hemodynamic stability and bleeding risk
• IV heparin infusion or LMWH depending on clinical context

D. Monitoring of Anticoagulation in ICU

E. Reversal of Anticoagulation

• UFH: Protamine sulfate 1 mg per 100 U heparin; caution - hypotension, bradycardia, anaphylaxis
• LMWH: Protamine partially reverses (~60-80%); 1 mg per 1 mg enoxaparin
• DOACs: Idarucizumab (dabigatran reversal); andexanet alfa (factor Xa inhibitors)

Q3. Airway Fires in Anesthesia (5 Marks)

Introduction

The Fire Triangle/Tetrahedron

1. Oxidizer (fuel for fire): O₂, N₂O - controlled by the anesthesiologist
2. Ignition/Heat source: electrosurgery (responsible in 90% of cases), laser, fiberoptic light - controlled by the surgeon
3. Fuel: drapes, ETT, sponges, gauze, alcohol-based skin prep, patient hair - controlled by the scrub nurse/surgeon

Risk Assessment - Pre-Surgical Timeout Score

Prevention Strategies

• Does the patient truly need supplemental O₂? Use room air if SpO₂ acceptable
• If FiO₂ > 0.3 is required AND high fire risk: seal the airway (cuffed ETT/LMA)
• Limit FiO₂ to ≤ 30% if using open system for high-risk head/neck procedures
• Do NOT use N₂O near the surgical field in high-risk cases
• Allow alcohol-based skin prep to dry for at least 3 minutes before draping

• Use lowest effective power settings
• Place electrosurgery unit in standby when not in use ("holster")
• Keep ignition sources away from the drapes

• Use wet/moistened sponges - less flammable
• Avoid alcohol accumulation under drapes
• Keep a basin of sterile irrigating fluid readily available

Management of an Airway Fire (STOP protocol)

1. STOP the procedure immediately
2. Halt all gas flow and disconnect circuit from the ETT
3. Remove the burning ETT immediately
4. Flood the airway with saline; remove burning material
5. Re-intubate the patient after the fire is extinguished (use rigid bronchoscopy to assess airway injury)
6. Examine and manage airway injury: thermal and chemical burns can cause edema, requiring prolonged intubation or tracheostomy
7. Post-event debriefing and documentation - mandatory

Special Considerations for Laser Airway Surgery

• Use laser-resistant ETTs (metal-wrapped: Mallinckrodt, Laser-Flex; or specific laser-resistant tubes)
• Inflate ETT cuff with saline (not air) - saline absorbs laser energy and prevents rapid cuff deflation
• Wrap the cuff area with wet saline-soaked sponges
• Maintain FiO₂ at the lowest acceptable level (ideally <30%)
• Avoid N₂O (supports combustion like O₂)

Q4. What is Fibrinogen Replacement Therapy? (5 Marks)

Introduction

Indications for Fibrinogen Replacement

• Fibrinogen level < 100 mg/dL in the setting of active bleeding
• Disseminated Intravascular Coagulation (DIC) with bleeding
• Massive transfusion - dilutional coagulopathy
• Liver failure / anhepatic phase of liver transplantation
• Obstetric hemorrhage: placental abruption, PPH, amniotic fluid embolism
• Congenital fibrinogen deficiency (afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia) - 1 per million incidence
• Management of bleeding after thrombolytic therapy (tPA-related intracranial hemorrhage)

Sources of Fibrinogen Replacement

• Cold-precipitate of fresh frozen plasma
• Contains: fibrinogen (~150-250 mg/bag), Factor VIII, vWF, Factor XIII, fibronectin
• Standard dose: 1-2 pools (10 units) for an adult; raises fibrinogen by ~50-100 mg/dL
• Trigger: fibrinogen < 100 mg/dL
• Thawed at 37°C; cannot be refrozen; must be ABO compatible

• Pasteurized, lyophilized, pathogen-reduced purified fibrinogen
• Advantages over cryoprecipitate:
  • Standardized fibrinogen content (1g per vial, 20 mg/mL on reconstitution)
  • Rapid preparation (no thawing required)
  • Lower infectious risk
  • No ABO matching required
  • Smaller volume - no risk of TACO/TRALI
• Dosing: 30-70 mg/kg IV; guided by ROTEM/TEG (target clot firmness A10 >7 mm)
• Increasingly preferred in perioperative and obstetric hemorrhage

• Contains all coagulation factors including fibrinogen, but fibrinogen concentration is low (~2 mg/mL)
• Large volumes required to significantly raise fibrinogen
• Second-line to cryoprecipitate/concentrate for isolated fibrinogen deficiency

Monitoring Fibrinogen Replacement

• Clauss method: functional fibrinogen assay (most widely used)
• ROTEM (rotational thromboelastometry) - FIBTEM A10 < 7 mm indicates fibrinogen deficiency; guides fibrinogen concentrate dosing
• TEG (thromboelastography) - functional fibrinogen (FF) channel

Key Clinical Points

• Fibrinogen is the first coagulation factor to reach critically low levels in massive hemorrhage and DIC
• Target fibrinogen > 150-200 mg/dL in major obstetric hemorrhage (higher threshold due to hypercoagulable state of pregnancy)
• Target > 100 mg/dL in general surgical/trauma hemorrhage
• In congenital afibrinogenemia: fibrinogen concentrate is preferred to cryoprecipitate

Q5. Management of Flail Chest in ICU (5 Marks)

Definition

Pathophysiology

• Paradoxical motion impairs bellows function of the chest wall
• Reduced vital capacity (VC reduced to ~50% of predicted)
• Reduced FRC
• Underlying pulmonary contusion is the key determinant of outcome (present in majority)
• Pain from multiple rib fractures leads to splinting, atelectasis, retained secretions, pneumonia
• Abnormal gas exchange (hypoxia, hypercapnia) drives decisions more than chest wall mechanics alone

ICU Management

1. Analgesia (CORNERSTONE of management)

• Adequate pain relief is paramount - prevents splinting, atelectasis, and allows effective cough
• Options (escalating):
  • Oral analgesics + NSAIDs
  • IV opioids / Patient-controlled analgesia (PCA)
  • Thoracic epidural analgesia (gold standard for rib fractures - reduces pneumonia, ICU stay, mortality)
  • Intercostal nerve blocks / Paravertebral blocks / ESPB (erector spinae plane block)

2. Respiratory Support

• Supplemental oxygen (maintain SpO₂ ≥ 94%)
• Physiotherapy and tracheobronchial toilet: clearance of secretions is essential
• Non-invasive ventilation (NIV/CPAP) - first-line for mild-moderate respiratory failure in awake patients who can protect their airway; acts as a pneumatic splint, improves gas exchange, reduces intubation rate, and improves morbidity/mortality compared to invasive ventilation
• Invasive mechanical ventilation: indicated if:
  • Respiratory failure unresponsive to NIV
  • GCS < 8 / inability to protect airway
  • Severe hemodynamic instability
  • Concurrent injuries requiring intubation
  • Use low-impedance ventilator modes that minimize subatmospheric pleural pressures

3. Fluid Management

• Cautious fluid resuscitation - overly aggressive fluids worsen pulmonary contusion and edema
• Balanced resuscitation in hemorrhagic shock

4. Surgical Fixation (Rib ORIF)

• Unable to wean from mechanical ventilation due to chest wall instability
• Concurrent thoracotomy for other injuries
• Persistent severe pain
• Progressive decline in pulmonary function
• Severe chest wall deformity

• Duration of mechanical ventilation
• ICU and hospital stay
• Infection rates
• May improve long-term pulmonary function

5. Monitoring

• Serial ABGs, SpO₂, respiratory rate, chest X-ray daily
• Consider CT thorax to assess extent of pulmonary contusion
• Pulse oximetry, invasive arterial line monitoring

Complications

• Early: Pneumothorax, hemothorax, pulmonary contusion, ARDS
• Late: Pneumonia (most common), empyema, ARDS, chest wall deformity, chronic pain

Pulmonary Function Recovery

• Without pulmonary contusion: VC and FRC return to baseline within ~6 months
• With pulmonary contusion: impaired function may persist for up to 4 years (fibrosis)

Q6. Role of Simulators in Anesthesia Training (5 Marks)

Introduction

Historical Development

• 1911: Mrs. Chase - first adult manikin for nurse training (Hartford Hospital)
• 1960: Resusci Anne (Laerdal) - CPR training
• 1969: Sim One - first electromechanical manikin in healthcare (University of Southern California); used for intubation practice and induction simulation
• 1976: Harvey - cardiology manikin (arterial pulse, BP, heart sounds simulation)
• 1986: CASE (Comprehensive Anesthesia Simulation Environment) - Stanford/Gaba group; first full-scale anesthesia simulator; led to development of Anesthesia Crisis Resource Management (ACRM) training

Types of Simulators

1. Computer-based case studies / screen simulators - pharmacology, physiology decision-making
2. Simple tabletop simulators - single-skill assessment (IV cannulation, intubation)
3. Part-task trainers - airway models, central line trainers, spinal/epidural trainers
4. Low-fidelity manikins - basic anatomy, BLS/ACLS
5. High-fidelity manikins (HFS) - full physiological simulation (Laerdal, Gaumard, CAE Healthcare); simulate rapid physiological changes; respond to medications and interventions
6. Standardized patients - communication, history taking, consent discussions
7. Virtual/augmented reality simulators - fiberoptic intubation, echocardiography, bronchoscopy, endoscopic procedures
8. Hybrid models - combine standardized patients with technology
9. Cadaveric models - surgical anatomy, advanced airway

Key Roles of Simulation in Anesthesia Training (Miller's Box 6.1)

• Procedural skills: intubation, IV/arterial access, regional blocks, central line insertion
• Common event management: induction, maintenance, emergence
• Teamwork and communication training

• New skills and procedures
• Exposure to rare events (malignant hyperthermia, anaphylaxis, can't intubate/can't oxygenate, local anesthetic systemic toxicity) - these cannot be ethically encountered in real patients
• Crisis Resource Management (CRM) training - adapted from aviation CRM; teaches leadership, communication, situational awareness, resource allocation under stress

• System integration
• Leading a team under crisis conditions
• Practice and process improvement
• Liability and morbidity/mortality reduction

Benefits of Simulation-Based Training

• Patient safety: "See one, do one, teach one" model is ethically and practically inadequate; simulation fills this gap
• Allows deliberate practice and repetition until mastery (behaviorist/automaticity learning)
• Provides a safe-to-fail environment for rare, high-stakes scenarios
• Enables debriefing and reflective learning - most important component of simulation education
• Supports assessment and credentialing of trainees and experienced practitioners
• Facilitates team training and interprofessional education
• Can be used for system-level testing (new protocols, equipment, workflow changes)

Crisis Resource Management (CRM) in Simulation

• Know the environment
• Anticipate and plan
• Call for help early
• Leadership and followership
• Distribute workload appropriately
• Mobilize all available resources
• Use all available information
• Closed-loop communication
• Cross-check and double-check
• Re-evaluate and adapt
• Use cognitive aids (checklists)
• Debrief after crises

Limitations of Simulation

• High cost of high-fidelity simulators and simulation centers
• Current simulators lack full fidelity (tactile feedback, realistic tissue planes)
• Not all clinical nuances can be replicated
• Risk of negative transfer if simulation is too inaccurate
• Requires trained facilitators and faculty
• Assessment tools (e.g., BARS, OSAT) are still being validated

Future Directions

• Artificial intelligence-driven adaptive simulation scenarios
• Extended reality (XR) / virtual reality with haptic feedback
• Telementoring and remote simulation
• Integration with electronic health records for realistic scenario data

Summary Table